<DOC>
	<DOC>NCT00174616</DOC>
	<brief_summary>Primary objective: - Pathological complete response (ypT0N0) rate Secondary objectives: - Histopathological R0 resection rate - Pathological downstaging (ypT0-T2N0) rate - One month surgical complication rate - Predictive value of pre-operative MRI for surgical, pathological and clinical outcomes - Safety - Local and distant recurrence rates - Progression-free survival - Overall survival</brief_summary>
	<brief_title>CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven adenocarcinoma of the rectum (Tumour ≤ 12 cm from the anal verge) No evidence of distant spread No prior therapy for chemotherapy or radiation therapy for rectal cancer Patient considered locally advanced by MRI: Tumour beyond mesorectal fascia, or Tumour ≤ 2mm from mesorectal fascia, or T3 tumour &lt; 5cm from anal verge For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception No peripheral neuropathy &gt; grade1 ECOG PS ≤ 2 ANC &gt; 1,500 x 10^9/L Platelets &gt; 100,000 x 10^9/L Creatinine &lt; 1.5 x IULN Bilirubin &lt; 1.5 IULN SGPT (ALT) &lt; 2.5 IULN No preexisting condition which would deter chemoradiotherapy No uncontrolled diarrhoea or fecal incontinence No significant small bowel (&gt; 200cc or 6X6X6cm) delineated within the radiation fields No other serious uncontrolled concomitant illness Informed consent signed The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>